ArticleBMC pregnancy and childbirth2026
Genetic risk assessment of pregnancy-associated venous thromboembolism: dual utility of maternal peripheral blood in NIPT and VTE evaluation.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveVenous thromboembolism (VTE) is a leading cause of maternal mortality, with pregnancy significantly increasing VTE risk due to physiological hypercoagulability. Current risk assessment methods, such as VTE scoring systems and D-dimer testing, have limitations in identifying high-risk individuals, highlighting the need for improved stratification.
methodsWhole genome sequencing (WGS) was performed on peripheral blood samples collected from 29 pregnant women with clinically diagnosed VTE during routine non-invasive prenatal testin (NIPT). The analysis focused on a curated list of 162 thrombosis-related genes (18 high-risk, 144 moderate/low-risk), incorporating detection of pathogenic variants, copy number variations (CNVs). Genetic risk factors were compared against conventional VTE risk scores and D-dimer levels. Additionally, a control group of 74 healthy pregnant women was included to enable allele frequency analyses.
resultsPathogenic/likely pathogenic variants were identified in 58.6% of cases (17/29), with TUBB1 and vWF as key contributors. 17 pathogenic CNVs were detected in 41.4% (12/29), involving PRSS1, C4A, etc. Allele frequency analysis highlighted 9 loci across 4 genes, indluding HLA-B, PRSS1, ACE, C4A linked to VTE susceptibility. Traditional VTE risk scores and D-dimer levels showed limited predictive ability, particularly in cases with low clinical risk scores but high genetic risk. Notably, among the 11 women with a pre-delivery VTE score of 0, 7 had genetic predispositions. Similarly, among the 15 women with low pre-delivery D-dimer levels, 9 had genetic risk, and among the 5 women with low D-dimer levels at 24 h postpartum, 3 had genetic risk. These findings collectively highlight the inability of traditional markers to capture hidden genetic risk in pregnancy-associated VTE.
conclusionsThe dual use of NIPT samples for VTE genetic assessment reduces invasive procedures and costs, offering a novel approach to optimize risk stratification, particularly for individuals with low traditional risk scores but high genetic susceptibility. These findings support integrating genetic screening into prenatal care to enable personalized prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.